In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
This rapid risk assessment (RRA) addresses the risk of importation of Rift Valley fever (RVF) virus (RVFV) and further spread of the virus within the European Union/European Economic Area (EU/EEA) in relation to the recent increase in cases reported on Mayotte, France.
The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
This document assesses the risk to human health posed by a multi-country incident of botulism neurotoxin type E, possibly associated with consumption of a commercially-available dried and salted fish product.
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to estimate the prevalence of hepatitis B and C in the general population and specific population subgroups in the EU/EEA Member States. This review is an update of an earlier review covering the period 2000–2009.
This rapid risk assessment monitors the threat posed by Rift Valley fever (RVF) which has been reported in regions of eastern and southern Africa, and in most of the sub-Saharan and West African countries.
ECDC and EFSA have assessed the risk to the EU/EEA posed by a fatal human case of Bacillus anthracis infection in Bulgaria and concluded that this event represents a negligible risk to other EU/EEA countries.
At the request of the European Commission, ECDC performed a risk assessment after six cases of wound botulism were reported in Norway among people who had injected heroin. As this is an ongoing problem, some relevant measures are proposed for consideration by other EU/EEA Member States.
This is an update to the joint rapid risk assessment published on 6 July 2012 by ECDC and EMCDDA on anthrax cases among injecting drug users in Germany. This is in response to further cases in France and Denmark. It contains information updated up to the 13 July 2012.